Compositions and methods for treating neurological and other disorders
Methods for treating neurological and other disorders, including autoimmune disorders are described. Also described is a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. Further a method is described that includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.
1. A method for treating a disorder in a patient, the method comprising administering to the patient in need of such treatment a therapeutically effective amount of a composition comprising a peptide comprising a Toll-like Receptor 2 (TLR2)-interacting domain of myeloid differentiation primary response 88 (MyD88), wherein the TLR2-interating domain of MyD88 comprises the sequence PGAHQK (SEQ ID NO: 1), wherein the therapeutically effective amount is an amount that at least reduces TLR2-MyD88 signaling and wherein the disorder is a neurological disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington's disease and multiple system atrophy.
2. The method of claim 1 , wherein the peptide comprising a TLR2-interacting domain of MyD88, further comprises Antennapedia homeodomain.
3. The method of claim 2 , wherein the Antennapedia homeodomain is linked by the C-terminal of the Antennapedia homeodomain to the N-terminal of the sequence PGAHQK (SEQ ID NO: 1).
4. The method of claim 1 , wherein the peptide comprising a TLR2-interacting domain of MyD88 is drqikwfqnrrmkwkkPGAHQK (SEQ ID NO: 2).
5. The method of claim 1 , wherein the composition further comprises at least one pharmaceutically acceptable carrier.
6. The method of claim 1 , wherein the composition is administered intranasally.
7. The method of claim 1 , wherein the patient is a human patient.